Meeting
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Phase I trial of the programmed death receptor 1 (PD-1) inhibitor, BI 754091, in patients (pts) with advanced solid tumors.
Authors
Melissa Lynne Johnson
Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN
Melissa Lynne Johnson, Manish R. Patel, Lillian L. Siu, Mark Kozloff, Raid Aljumaily, Ulka N. Vaishampayan, Mabrouk M. Elgadi, Miaomiao Ge, Christine Duffy, Ralph Graeser, Sheetal Vinay Khedkar, Suzanne Fields Jones, Howard A. Burris
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies
Sub Track
Immune Checkpoints and Stimulatory Receptors
Clinical Trial Registration Number
NCT02952248
Citation
J Clin Oncol 36, 2018 (suppl 5S; abstr 212)
DOI
10.1200/JCO.2018.36.5_suppl.212
Abstract #
212
Poster Bd #
M2
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.
First Author: Judy S. Wang
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial.
First Author: Jing Huang
Poster
2022 ASCO Annual Meeting
A first-in-human phase I dose-escalation trial of the B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab (BI 754091) in patients with advanced solid tumors expressing B7-H6.
First Author: Gerald Steven Falchook
Poster
2021 ASCO Annual Meeting
A phase I study of an IDO inhibitor (SHR9146) plus camrelizumab and in combination with/without apatinib in patients with advanced solid tumors: Safety and efficacy analysis.
First Author: Ying Cheng